| Customization: | Available |
|---|---|
| Varieties: | Infectious Disease Prevention Medicine |
| Component: | Chemical Synthetic Drugs |
|
Still deciding? Get samples of US$ 80/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| CERTIFICATE OF ANALYSIS | |||
| Product Name | Florfenicol | Batch No. | FB201806056 |
| Packaging | 25kg/drum | Quantity | 950kgs |
| Packing Date | JUN.18,2018 | Reporting Date | JUN.18,2018 |
| MFG Date | JUN.16,2018 | Exp. Date | JUN.15,2020 |
| Standard | CVP 2015 | ||
| Test Items | Specification | Test Results | |
| Description | White or almost white crystalline powder |
Almost white crystalline powder |
|
| Solubility |
very soluble in N,N-Dimethylformamide, soluble in methanol,sparingly soluble in glacial acetic acid, very slightly soluble inchloroform, Practically insoluble in water |
Complies | |
| Melting Point | 152.0ºC~156.0ºC | 155.1ºC | |
| Optical rotation | -16°~-19° | -17.7° | |
| ldentification |
(1)The retention times of the major peak of the sample 'solutionshould correspond to that of the standard solution as obtained inthe assay. |
Complies | |
|
(2).The Infrared absorption spectrum obtained from the testsample is consistent with that from reference standard. |
Complies | ||
| PH | 4.5~6.5 | 6.1 | |
| Chloride | ≤0.02% | <0.02% | |
| Fluorine | ≤0.48% | 4.90% | |
| Related substances |
1)Peak area of single impurity peak should be NMT the referencesolution's main peak 0.5 times (0.5%) |
≤0.02% | |
| 2)Peak area of total impurities shoule be NMT the peak area of reference solution 2 times (2.0%). |
0.50% | ||
| Loss on Drying | ≤0.5% | 0.10% | |
| Residue on Ignition | ≤0.1% | 0.03% | |
| Heavy Metals | ≤20ppm | <20ppm. | |
| ASSAY | ≥98.0% | 99.10% | |
| Conclusion: The results comply with CVP 2015. | |||
1) For pigs arthritis, pneumonia, atrophic rhinitis and other diseases caused by streptococcus, pneumococcal, haemophilus.
2) Auxiliary treatment of breathing and reproduction obstacle syndrome, Aujeszky's Disease, bacterial infection caused by influenza.
3) An antibacterial. Fluorinated derivative of thiamphenicol. Inhibits bacterial protein synthesis by binding to ribosome 50S and 70S subunits.
){kind=link}